SCHEMBL5459876

SCHEMBL5459876

COc1ccc(-c2ccccc2)cc1NC(=O)c1c[c]ccc1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 2/20 0.60
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
POLB P06746 1/20 0.56
HDAC8 Q9BY41 2/20 0.53
HDAC1 Q13547 3/20 0.52
HDAC6 Q9UBN7 1/20 0.52
ABCC1 P33527 4/20 0.49
KCNMA1 Q12791 1/20 0.49
ABCB1 P08183 4/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MAPT P10636 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
NR1H4 Q96RI1 1/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
HDAC2 Q92769 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5464230 0.84 TP53 (0.59) MEN1KMT2APOLBSMN1; SMN2MAPT
SCHEMBL5468423 0.83 POLB (0.57) MEN1KMT2APOLBKCNMA1SMN1; SMN2
SCHEMBL5460406 0.82 KCNMA1 (0.62) MEN1KMT2APOLBHDAC8HDAC1
SCHEMBL14363388 0.81 ACLY (0.62) ACLYMEN1KMT2APOLBHDAC8
SCHEMBL5463645 0.81 HTT (0.51) MEN1KMT2APOLBKCNMA1SMN1; SMN2
SCHEMBL330588 0.81 ACLY (0.74) ACLYMEN1KMT2APOLBHDAC8
SCHEMBL12368165 0.80 MEN1 (0.65) ACLYMEN1KMT2APOLBHDAC8
SCHEMBL5461743 0.80 KDM4E (0.54) MEN1KMT2APOLBKCNMA1SMN1; SMN2
SCHEMBL5463923 0.76 KDM4E (0.48) MEN1KMT2AKCNMA1SMN1; SMN2MAPT
SCHEMBL5468424 0.76 NPC1 (0.56) MEN1KMT2APOLBSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 ACLY 2561/4885MEN1 2892/4885KMT2A 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.